Cohance Lifesciences Limited (BOM:543064)
India · Delayed Price · Currency is INR 429.40
-1.70 (-0.39%)
At close: Jun 1, 2026
Cohance Lifesciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 22,686 | 11,976 | 10,514 | 13,403 | 13,202 |
Other Revenue | 340.9 | - | - | - | - |
| 23,026 | 11,976 | 10,514 | 13,403 | 13,202 | |
Revenue Growth (YoY) | 92.27% | 13.91% | -21.56% | 1.52% | 30.75% |
Cost of Revenue | 6,626 | 3,757 | 3,716 | 5,882 | 5,741 |
Gross Profit | 16,400 | 8,219 | 6,797 | 7,521 | 7,461 |
Selling, General & Admin | 5,077 | 2,562 | 1,396 | 1,218 | 1,024 |
Research & Development | - | - | - | - | 103.55 |
Other Operating Expenses | 6,712 | 1,601 | 1,311 | 561.82 | 526.62 |
Operating Expenses | 13,663 | 4,938 | 3,253 | 2,259 | 2,045 |
Operating Income | 2,738 | 3,281 | 3,544 | 5,262 | 5,416 |
Interest Expense | -372.4 | -123.5 | -74.5 | -128.11 | -62.31 |
Interest & Investment Income | - | 12.7 | 19.3 | 58.32 | 0.69 |
Earnings From Equity Investments | - | - | - | - | 411.12 |
Currency Exchange Gain (Loss) | - | 116.6 | 81.2 | 214.38 | 164.21 |
Other Non Operating Income (Expenses) | - | 12.4 | 66.8 | 32.9 | 0.02 |
EBT Excluding Unusual Items | 2,365 | 3,299 | 3,637 | 5,439 | 5,930 |
Merger & Restructuring Charges | - | -302.6 | -31.1 | - | - |
Gain (Loss) on Sale of Investments | - | 409.6 | 449.1 | 156.87 | 636.14 |
Gain (Loss) on Sale of Assets | - | -1.1 | -0.7 | -0.07 | 106.03 |
Other Unusual Items | -294.7 | 34.3 | 2.7 | 1.17 | 3.73 |
Pretax Income | 2,070 | 3,439 | 4,057 | 5,597 | 6,676 |
Income Tax Expense | 569.2 | 791.5 | 1,054 | 1,484 | 2,138 |
Earnings From Continuing Operations | 1,501 | 2,648 | 3,003 | 4,113 | 4,538 |
Minority Interest in Earnings | 291.1 | 31 | - | - | - |
Net Income | 1,792 | 2,679 | 3,003 | 4,113 | 4,538 |
Net Income to Common | 1,792 | 2,679 | 3,003 | 4,113 | 4,538 |
Net Income Growth | -33.09% | -10.79% | -26.99% | -9.37% | 25.24% |
Shares Outstanding (Basic) | 382 | 255 | 255 | 255 | 255 |
Shares Outstanding (Diluted) | 383 | 256 | 255 | 255 | 255 |
Shares Change (YoY) | 49.70% | 0.49% | - | - | - |
EPS (Basic) | 4.69 | 10.52 | 11.80 | 16.16 | 17.83 |
EPS (Diluted) | 4.68 | 10.45 | 11.80 | 16.16 | 17.83 |
EPS Growth | -55.20% | -11.45% | -26.99% | -9.37% | 25.27% |
Free Cash Flow | 1,484 | 1,325 | 3,329 | 1,713 | 2,548 |
Free Cash Flow Per Share | 3.88 | 5.18 | 13.08 | 6.73 | 10.01 |
Dividend Per Share | - | - | - | 3.000 | 2.000 |
Dividend Growth | - | - | - | 50.00% | - |
Gross Margin | 71.22% | 68.63% | 64.65% | 56.11% | 56.51% |
Operating Margin | 11.89% | 27.40% | 33.71% | 39.26% | 41.02% |
Profit Margin | 7.78% | 22.37% | 28.56% | 30.69% | 34.37% |
Free Cash Flow Margin | 6.45% | 11.06% | 31.66% | 12.78% | 19.30% |
EBITDA | 4,611 | 4,056 | 4,090 | 5,726 | 5,795 |
EBITDA Margin | 20.02% | 33.87% | 38.90% | 42.72% | 43.89% |
D&A For EBITDA | 1,873 | 774.9 | 546 | 464.6 | 378.64 |
EBIT | 2,738 | 3,281 | 3,544 | 5,262 | 5,416 |
EBIT Margin | 11.89% | 27.40% | 33.71% | 39.26% | 41.02% |
Effective Tax Rate | 27.49% | 23.01% | 25.98% | 26.52% | 32.02% |
Revenue as Reported | 23,026 | 12,561 | 11,133 | 13,867 | 14,126 |
Advertising Expenses | - | 57.2 | 34.8 | 34.89 | 18.83 |